Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder

Medicus Pharma (NASDAQ:MDCX) said on Friday it has submitted an application to the US Food and Drug Administration seeking orphan drug designation for its SkinJect therapy to treat basal cell carcinoma in patients with Gorlin Syndrome, a rare genetic condition marked by recurring skin cancers. The company said the filing expands its SkinJect program into an area of high unmet medical need, where treatment options are limited and often rely on repeated surgical procedures that can lead to cumulative physical and psychological burden.